{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-000027","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2022-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.897079+00:00","generated_at":"2026-06-27T20:39:07.280740+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Edgewise reports positive Phase 1b results for EDG-5506 in Becker MD: biomarkers reduced 71-83%","bullets":["EDG-5506 well tolerated with no serious adverse events; dizziness was mild and transient.","CK reduced 71% and TNNI2 reduced 83% after two weeks, near healthy volunteer levels.","Plasma and muscle exposures exceeded pharmacologically active levels from preclinical models.","No effect on voluntary grip, shoulder, or hip strength; ARCH open-label study enrolling.","Management webcast today at 9 a.m. ET to discuss findings."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-000027","json":"https://secwatch.observer/filing/0001157523-22-000027.json","markdown":"https://secwatch.observer/filing/0001157523-22-000027.md","text":"https://secwatch.observer/filing/0001157523-22-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000115752322000027/0001157523-22-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000115752322000027/a52557938.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T20:39:07.280740+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}